FDA Alerts

FDA approves first IL-23 inhibitor for psoriatic arthritis

The U.S. Food and Drug Administration has approved guselkumab (TREMFYA; Janssen Pharmaceutical), the first selective interleukin (IL)-23 inhibitor for active psoriatic arthritis. In two Phase 3 clinical trials, guselkumab was found to significantly improvedssigns and symptoms in joints, skin, and soft tissue in adults with active psoriatic arthritis Guselkumab is...